Samumed said today that the FDA awarded orphan drug status to its inhaled idiopathic pulmonary fibrosis therapy, SMo4646.
The IPF therapy is administered using a nebulizer and can be used as a montherapy or in combination with pirfenidone or nintedanib, according to the San Diego-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Samumed wins orphan drug status for inhaled IPF therapy appeared first on MassDevice.